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Abstract: Polymyxins are valuable antimicrobials for the management of multidrug-resistant
Gram-negative bacteria; however, nephrotoxicity associated with these drugs is a very common
side effect that occurs during treatment. This article briefly reviews nephrotoxic mechanisms and
risk factors for polymyxin-associated acute kidney injury (AKI) and discusses dosing strategies
that may mitigate kidney damage without compromising antimicrobial activity. Polymyxins have a
very narrow therapeutic window and patients requiring treatment with these drugs are frequently
severely ill and have multiple comorbidities, which increases the risk of AKI. Notably, there is a
significant overlap between therapeutic and toxic plasma polymyxin concentrations that substantially
complicates dose selection. Recent dosing protocols for both colistin and polymyxin B have been
developed and may help fine tune dose adjustment of these antibiotics. Minimizing exposure
to modifiable risk factors, such as other nephrotoxic agents, is strongly recommended. The dose
should be carefully selected, particularly in high-risk patients. The administration of oxidative
stress-reducing drugs is a promising strategy to ameliorate polymyxin-associated AKI, but still
requires support from clinical studies.
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1. Introduction
Polymyxin antibiotics were introduced in the 1950s for the treatment of Gram-negative infections.
In the 1970s, they were progressively abandoned as a therapeutic due to the development and launch of
newer and less toxic antibiotics [1,2]. Owing to the emergence of carbapenem-resistant Gram-negative
bacteria near the end of the last century, notably in the early 2000s, and the lack of new therapeutic
options, polymyxins re-emerged in clinical practice [1,2]. Since then, the toxicity associated with these
compounds, particularly nephrotoxicity, has been of great concern.
As reported in earlier studies, the emerging experience with both polymyxins, colistin
(administered as the prodrug colistimethate [CMS]) and polymyxin B, indicated that up to half of the
patients receiving these drugs presented nephrotoxicity [3]. However, it became clear that multiple
definitions for nephrotoxicity impaired a more accurate estimate of the real incidence of acute kidney
injury (AKI) in patients treated with polymyxins [3]. More recent studies using standardized criteria
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for AKI, such as Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Network
(AKIN) and Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE), have
been published, among which, a recent meta-analysis showed that the occurrence of AKI remained
undesirably high with mean rates of 31.3%, 32.6% and 39.4%, respectively [4]. Patients treated
with colistimethate may have higher AKI rates than those treated with polymyxin B [5], although a
more recent meta-analysis showed that there was no significant difference of nephrotoxicity between
polymyxins [4].
Strategies to avoid or minimize nephrotoxicity have become a challenge for clinicians treating
patients with polymyxins since many associated risk factors for AKI are very common in the typical
patient who needs a polymyxin-based therapy, and most of them are non-modifiable. The purpose of
this article is to discuss the dosing management of these valuable antibiotics in order to avert or
decrease kidney injury in patients treated with polymyxins. Other strategies to decrease nephrotoxicity
and a brief review of the mechanisms of toxicity and risk factors for polymyxin-associated AKI are
also presented.
2. Mechanisms of Nephrotoxicity
Knowledge of the polymyxin-induced mechanisms of nephrotoxicity has significantly increased
in the last decade, helping in the exploration of different strategies to reduce renal damage caused by
these drugs. A starting point in the pathway of events that leads to nephrotoxicity is avid proximal
tubule reabsorption that both polymyxins (polymyxin B and colistin) undergo in the kidneys [6].
In this process, there is a substantial intracellular accumulation of the drug which is mediated by the
endocytic receptor, megalin, as well as other transporters [7]. The high intracellular concentration of
polymyxins has been demonstrated in both human (HK-2) and rat (NRK-52E) kidney cells, which
allowed experiments in animal and cell culture models to further explore this phenomenon [8,9].
The accumulation of polymyxins leads to drug-induced cell apoptosis which in turn results in decreased
renal function and histopathological damage. Animal studies have shown that dilated renal tubules,
cast formation and tubular necrosis occur in a dose- and time-dependent fashion after exposure to
polymyxins [10]. The major pathways that result in kidney cell apoptosis involve the activation of
death receptors, mitochondrial damage, and changes in endoplasmic reticulum function and the
autophagy process [8,10,11].
The death receptor pathway is one of the most sensitive in the cell damage process [10]. Increased
membrane-anchored FasL in rats exposed to polymyxins binds to Fas (death receptor), then triggers
caspase-8 activation and, subsequently, caspase-3 activation, which is the final executioner of DNA
fragmentation and cellular apoptosis [8]. The activation of the death receptor pathway liberates reactive
oxygen species, increasing oxidative stress, which in turn contributes to mitochondrial fragmentation.
Mitochondrial morphology is significantly changed when exposed to polymyxins, changing
from its normal filamentous form to a fragmented version. The change in mitochondrial morphology
results in the loss of its membrane potential and increased superoxide production, which leads to more
mitochondrial damage. This intrinsic mitochondrial pathway activates proapoptotic proteins, such as
caspase-9, which also culminates in caspase-3 activation and cell death [8]. Moreover, the endoplasmic
reticulum, when under prolonged stress, activates proapoptotic genes, such as growth arrest and
DNA damage 153 (GADD153), which activates caspase-12, followed by the activation of downstream
caspases, leading to cellular apoptosis [10]. Finally, the normal autophagy process, responsible
for removing damaged proteins and organelles, can be decreased when exposed to high doses of
polymyxins. This contributes to a malfunctioning of the balance between apoptosis and autophagy
and leads to worse control of cell damage [10].
In summary, polymyxins induce pan-caspase activation in a time- and concentration-dependent
manner through different pathways, which ultimately leads to cell apoptosis. Oxidative stress
generated by this process is responsible for further activating these pathways, maintaining the cycle
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that leads to kidney cell death [8]. Ultimately, understanding the mechanisms of polymyxin renal
toxicity should help point to future strategies in the management of patients receiving these drugs.
3. Risk Factors for Nephrotoxicity
The development of AKI is the most common and undesired adverse effect of polymyxins.
The occurrence of AKI during treatment is associated with worse prognosis, including higher mortality
rates [12–14]. Furthermore, among patients who developed AKI during polymyxin therapy, a higher
incidence of chronic renal failure has been recently demonstrated [15,16]. Thus, decreasing the
incidence of AKI during treatment with polymyxins may have short- and long-term clinical impacts in
patients treated with these antibiotics.
In order to limit kidney injury during treatment with polymyxins, lowering exposure to other risk
factors for AKI is an appealing strategy. Unfortunately, many polymyxin-associated AKI risk factors
reported are not modifiable. In addition, although some chronic comorbid conditions, notably diabetes,
have been identified as risk factors for AKI [17–21], patients requiring treatment with polymyxins are
commonly severely ill and have multiple chronic conditions that together may increase drug-induced
injury to the kidneys [18,22–27].
Among the non-modifiable risk factors, higher age has been reported in many
studies [14,17,19,22,28–30]. However, it is not known whether there is a linear effect of age on the
risk of AKI or whether the risk may increase over a given age. It is interesting that higher weight also
increases the risk of AKI and this effect has been shown to be independent of the dose administered
to the patients [14,19,31]. In addition, hypoalbuminemia has been shown to increase the risk of AKI
in some studies [20,25,32,33], although the mechanism for the association is not known [33]. At this
time, it is not considered appropriate to modify the daily dose of colistimethate in patients with
hypoalbuminemia [34].
There are a few potentially modifiable risk factors that have been identified. One potentially
modifiable risk factor that has been reported is the use of concomitant nephrotoxic drugs. Concomitant
use of one or more non-specified nephrotoxic drug has been reported in some studies [17,23,27,35],
while loop diuretics [18,36], calcineurin inhibitors [20], non-steroidal anti-inflammatory drugs [32]
and intravenous contrast media [37] have been identified as risk factors among non-antimicrobial
drugs. Vancomycin has been reported in some studies [31,37–39], while aminoglycosides [30] and
rifampin [35] have been reported in single studies, although randomized clinical trials with rifampin
in association with colistin have not demonstrated a higher incidence of nephrotoxicity in patients
in rifampin arms [40,41]. In fact, there is some incipient evidence that combination therapy may
decrease the risk of AKI. In a recent randomized clinical trial comparing colistin with colistin plus
meropenem for severe Gram-negative infections, the incidence of AKI was significantly higher in
the monotherapy group (48%) compared with the combination group (29%) (p = 0.001), which was
determined by differences in Injury (14% vs. 6%, respectively) and Failure (17% vs. 8%, respectively),
categories of RIFLE [42]. There were no differences between groups regarding colistin dose (although
total cumulative doses were only reported for patients alive on day 14) and concomitant use of
nephrotoxic drugs [42]. More recently, a meta-analysis evaluating the safety and efficacy of colistin
alone or in combination in adults with Acinetobacter baumannii infection has also found that the
incidence of nephrotoxicity was higher in the monotherapy group (odds ratio = 1.66, 95% confidence
interval = 0.99–2.78, p = 0.05) [43]. Additionally, although it may be associated with the oxidative
stress-reducing properties of minocycline [44], a combination of colistin with minocycline was shown
to reduce the incidence of AKI in an observational study [45]. We speculate that combination therapy,
regardless of its impact on overall mortality, owing to higher microbiological effectivity, might result
in less general inflammatory response and/or earlier recovery from sepsis, thus decreasing the
dysfunction of organs, including the kidneys.
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The most important variable associated with the development of nephrotoxicity is polymyxin
dose [14,20,24,35–39,46,47]. Although evaluated in a few studies, the administration of loading doses
has been found to increase the risk of nephrotoxicity in some studies [28,48], but not others [18,23,38,49].
Additionally, and possibly related to total drug exposure, a longer duration of treatment has been
identified by some authors [21,29]. The issue of doses and plasma polymyxin concentrations [27,50]
will be discussed in the following section.
4. Dosing Strategies to Reduce Nephrotoxicity
While a greater amount of preclinical, clinical pharmacological and toxicological data are available
for colistin than for polymyxin B, it is evident that both agents have very low therapeutic indices.
For each agent, the substantial overlap in the plasma concentrations that are generally regarded as
being required for the desired antibacterial effect and those that may predispose to nephrotoxicity
mandates that dosing strategies must be carefully considered, as highlighted in the recently published
international consensus guidelines for the optimal use of the polymyxins [51]. In regard to careful
selection of a dosing strategy for each patient, it is important to be aware that sepsis arising from
an inadequately treated Gram-negative infection can also lead to kidney injury [52]. At the outset,
it is both relevant and important to consider the data that indicate the narrowness of the therapeutic
window of each of the polymyxins.
4.1. Colistin and Polymyxin B: Drugs with Very Narrow Therapeutic Windows
For colistin, an average steady-state plasma concentration (Css,avg) of 2 mg/L has been suggested
as a target level of exposure at the initiation of therapy, a time when the minimum inhibitory
concentration (MIC) of the organism causing infection may not be known [53,54]. Even if an estimate of
MIC is available at that time, it must be recognized that MIC measurements are subject to error [55].
The proposed plasma colistin Css,avg target of 2 mg/L corresponds to the MIC clinical breakpoint for
Pseudomonas aeruginosa and A. baumannii and the epidemiological cut-off value for Klebsiella pneumoniae
and several other Gram-negative pathogens [56]. The target to guide therapy at the initiation of
treatment was based on pharmacokinetic–pharmacodynamic (PK–PD) data from murine models of
infection with P. aeruginosa and A. baumannii [57] and pharmacokinetic–toxicodynamic (PK–TD) data
on the relationship between the plasma colistin concentration and risk of nephrotoxicity in critically ill
patients [27,50,58] that together indicate the very narrow therapeutic window for colistin, as shown
diagrammatically in Figure 1.
A tentative target therapeutic range for plasma polymyxin B AUC24 at a steady state of
50–100 mg·h/L has recently been proposed; this corresponds to a plasma polymyxin B Css,avg
range of approximately 2–4 mg/L [59]. The lower end of this range was based on the aforementioned
murine PK–PD data for colistin against P. aeruginosa and A. baumannii [57], assuming similar in vivo
antibacterial effects of colistin and polymyxin B, and PK–PD data for polymyxin B against K. pneumoniae
infection in thighs of mice [60]. The upper end of the proposed polymyxin B concentration range was
from a PK–TD meta-analysis of previously published articles reporting nephrotoxicity rates in patients
treated with the drug. The meta-analysis revealed a statistically significant linear relationship between
the percentage of patients with a ≥25% decrease in creatinine clearance during polymyxin B therapy
and the plasma polymyxin B Css,avg [59]. The Css,avg associated with rates of mild nephrotoxicity
(≤25% decrease in creatinine clearance) in ≤40% of patients was estimated to be ~4 mg/L; however,
as discussed above for colistin nephrotoxicity, mild nephrotoxicity was observed in some patients with
lower concentrations.
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Figure 1. Diagrammatic representation of the very narrow therapeutic window of colistin, which is
based on two key considerations. The first consideration was the translation of PK–PD data from
murine thigh infection studies, in which subcutaneous colistin was used against infections caused by
either P. aeruginosa or A. baumannii [57]. In this infection model, an average value of approximately 12
for the ratio of the area under the free (unbound) plasma concentration versus the time curve over 24 h
(f AUC24) to the minimum inhibitory concentration (MIC) of the pathogen (f AUC24/MIC) was required
for a 2-log bacterial kill each of P. aeruginosa and A. baumannii [57]. Given that colistin is approximately
50% bound in plasma of critically ill patients, a f AUC24/MIC of 12 determined in mice translates to a
AUC24/MIC of 24 when considering the total plasma concentration in human patients [53,54]. Since an
AUC24 of 24 mg·h/L corresponds to an average steady-state plasma concentration (Css,avg) of 1 mg/L
(i.e., 24 mg·h/L divided by 24 h), translation of the murine PK–PD data to critically ill patients suggests
that, from an antibacterial perspective, the target Css,avg should correspond to the MIC of the infecting
organism. Thus, based on PK–PD data from thigh infection models in mice, a Css,avg of 2 mg/L may be
considered appropriate for treatment of an infection caused by an organism with an MIC of 2 mg/L,
which is the clinical breakpoint for P. aeruginosa and A. baumannii and the epidemiological cut-off value
for K. pneumoniae and several other Gram-negative pathogens [56]. The second important consideration
in proposing an initial target plasma colistin Css,avg of 2 mg/L was the clinical PK–TD data on the
relationship between the plasma colistin concentration and risk of nephrotoxicity in critically ill patients.
These data indicate that nephrotoxicity can occur even in the face of relatively low plasma colistin
concentrations and that the likelihood of nephrotoxicity substantially increases above a plasma colistin
Css,avg of approximately 2–3 mg/L [27,50,58].
Clearly, based on PK–PD data from murine thigh infection models and clinical PK–TD analyses,
plasma concentrations associated with nephrotoxicity overlap with those for antibacterial effect. It is
important to note that experimental lung infections in mice were substantially less responsive than
thigh infections to the systemic administration of each of the polymyxins [57,60]. This implies that the
ability of the parenteral administration of polymyxin to achieve concentrations in plasma associated
with antibacterial effects in the lung, while having acceptable potential for nephrotoxicity, is severely
compromised. In other words, the murine lung infection studies suggest greater overlap than that
based on the murine thigh infection studies in the plasma concentrations associated with the desired
(i.e., antibacterial) effect and the major undesired (i.e., nephrotoxic) effect.
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4.2. Implications of the Narrow Therapeutic Range for Dosing of Polymyxins
4.2.1. Choice of Polymyxin
As discussed above, there may be a greater margin of safety for polymyxin B compared to
colistin. Studies reported over the last decade and meta-analyses on the derived data suggest
that the risk of nephrotoxicity may be lower with polymyxin B [5,17,18,29,39,48,61,62], although
a recent meta-analysis that included a large number of older studies suggested that there was no
difference in nephrotoxicity prevalence between the two polymyxins [4]. It should be noted that
several of the studies, especially from earlier literature, are difficult to interpret due to confounding
influences, diversity in definitions of nephrotoxicity and lack of detail [63]. In addition, as reviewed
previously [64,65] and discussed below, polymyxin B has PK characteristics that render it generally
easier to use than is the case for colistin. Currently, it is suggested that where clinicians have a
choice between the two polymyxins, polymyxin B is the preferred agent for invasive infections [51,65].
Colistimethate (the inactive prodrug of colistin [66,67]) is preferred for urinary tract infections, as the
extensive urinary excretion of the prodrug followed by spontaneous conversion to colistin within
the urinary tract leads to high concentrations of colistin in urine [68,69]. Colistimethate may also
be the preferred polymyxin preparation for administration via the intraventricular or intrathecal
route [70–76]; there is less published information relating to the administration of polymyxin B via
these routes.
4.2.2. To Load or Not to Load?
As discussed in Section 3, the initiation of polymyxin therapy with a loading dose has not been
conclusively shown to be a risk factor for nephrotoxicity. Due to the time required for plasma colistin
concentrations to rise after initiating colistimethate therapy, a loading dose should be used [51]. Even if
this increased the risk of nephrotoxicity, the harm of a delay in achieving therapeutic plasma levels may
be worse. For polymyxin B, in the absence of evidence of increased risk for nephrotoxicity, a loading
dose is recommended, especially for severe infections and for bacteria with a high MIC.
4.2.3. Selection of the Daily Maintenance Dose at Initiation of Therapy and Ongoing Optimization
Colistin
Colistin displays rather complex PK characteristics [1,53,54,64,77,78]. Following the intravenous
administration of colistimethate to patients with good renal function, extensive renal excretion of the
prodrug occurs and only a relatively small proportion (20–30% or less) of the administered dose of
colistimethate is available for conversion to colistin within the body (excluding the urinary tract).
Renal function, as assessed by creatinine clearance, is the only patient factor that has been shown to
influence the plasma colistin Css,avg during ongoing therapy with colistimethate [54,79]. As clinical
PK–TD analyses have shown the direct relationship between the plasma colistin Css,avg and the risk of
nephrotoxicity [27,50,58], at the initiation of therapy, it is important to select a daily maintenance
dose of colistimethate that is considered appropriate given the baseline creatinine clearance of the
patient [51]. Based on a population PK analysis of data from 214 adult critically ill patients, an algorithm
incorporating creatinine clearance has recently been developed to enable the selection of a daily dose of
colistimethate to achieve a desired plasma colistin Css,avg (2 mg/L, or a lower concentration if that
is deemed appropriate) [54]. The algorithm was developed such that, across various categories of
creatinine clearance values, >80% of patients would achieve the desired plasma colistin Css,avg and,
to minimize the potential for colistin-associated nephrotoxicity, <30% of patients would achieve a
plasma exposure of greater than twice the desired target.
It is essential to appreciate the following points regarding the application of the algorithm [54].
First, because of the very wide inter-patient variability in the apparent clearance of formed colistin
(even at a given creatinine clearance) and the narrow therapeutic window of colistin, it is not possible
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that less than 30% of patients are likely to achieve greater than twice the desired antibacterial target
while simultaneously at least 80% are likely to achieve the desired antibacterial target. Second,
because of the rapid clearance of colistimethate in patients with creatinine clearance, ≥80 mL/min,
it is only possible to achieve a plasma colistin Css,avg of 2 mg/L in less than 40% of such patients,
even with a daily dose of 360 mg of colistin base activity (corresponding to ~10.9 million international
units (IU) per day). It is regarded as unwise to increase the daily dose above this level as that may
increase the risk of nephrotoxicity. Third, it is axiomatic that the application of the algorithm provides
no assurance that a plasma colistin Css,avg equal to or greater than the desired target will be achieved
or indeed that a plasma concentration more than twice the target will not be achieved. Finally, there is
no guarantee that the achievement of a plasma colistin Css,avg less than twice the desired target, or
indeed less than the target itself, will not predispose to nephrotoxicity.
The algorithm is simply a tool to enable the estimation of what may be regarded as a reasonable
daily maintenance dose at the initiation of therapy [54]. The algorithm may also be used for renal-based
dose adjustments during ongoing therapy if there is a change in creatinine clearance [51]. For example,
in the event of a decrease in creatinine clearance (for whatever reason) where a decision is made to
continue therapy with colistimethate, the daily dose should generally be adjusted downwards to
maintain the original target concentration. If a reliable estimate of the MIC of the infecting organism
and/or the clinical circumstances suggest that a lower plasma concentration may be adequate, it may be
appropriate to apply the algorithm to target a plasma colistin Css,avg lower than the original target
concentration. These approaches are intended to minimize the potential for a colistin-associated
exacerbation of the already established renal function decline.
As discussed above, the very substantial inter-patient variability in the apparent clearance of
colistin (and, hence, the plasma colistin Css,avg achieved from a particular daily dose of colistimethate)
and the narrow therapeutic window impose limitations on the application of the algorithm [54].
It is highly desirable that ongoing therapy with colistimethate is guided by reliable measurement of
the plasma colistin concentration via timely access to a therapeutic drug monitoring/management
(TDM) service [51], as available in some settings [80–83]. Knowledge of the plasma colistin
concentration enables the optimization of the daily dose of colistimethate to maximize the likelihood of
a desired antibacterial outcome, while minimizing the risk of nephrotoxicity. Unfortunately, reliable
determination of the plasma colistin concentration in samples collected from patients receiving
colistimethate is extremely challenging, not least because the circulating concentration of colistimethate
is higher than that of colistin, especially during the first several hours of a dosage interval.
Microbiological assays cannot be used because of the ongoing conversion of colistimethate to colistin
during the incubation procedure of the assay [67] and issues related to the sensitivity and specificity of
such assays. Even with chromatographic assay methods, there is a need for very careful sample
collection, processing, storage and analysis procedures to avoid ongoing conversion of the prodrug to
colistin after a blood sample has been collected from the patient [64,84–86]. Such difficulties do not
arise with polymyxin B because it is not administered as a prodrug; this is one of several features that
favors the use of polymyxin B over colistimethate for most types of invasive infections [64].
Polymyxin B
Typically, less than 5% of an intravenous dose of polymyxin B is excreted in urine in the form of
the unchanged drug [87,88]. It is, therefore, not surprising that renal function, as assessed by creatinine
clearance, does not influence the clearance of polymyxin B to a clinically significant degree [87–92].
At the initiation of maintenance therapy, a daily dose of 1.5 to 3 mg/kg (equivalent to 15,000 to
30,000 IU/kg) of polymyxin B is generally used, depending on the MIC (often not known at initiation of
therapy), and the site and severity of infection. Renal-based dose selection is not relevant for polymyxin
B because of the lack of clinically significant influence of creatinine clearance on the clearance of the
drug [51]. There is limited experience with absolute doses ≥200 mg per day and infusion-related
adverse effects may increase with such doses [23,93]. If a decrease in creatinine clearance occurs
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during therapy, the polymyxin B daily dose should not be decreased, particularly in a patient with a
life-threatening or deep-seated infection or if the pathogen’s MIC is >1 mg/L.
Recently, Lakota et al. [59] investigated the application of adaptive feedback control (AFC) in
silico to optimize and individualize dosage regimens of polymyxin B, with the aim of maximizing
the potential antibacterial effect and minimizing the likelihood of nephrotoxicity. AFC, an approach
involving the use of plasma drug concentration measurements (i.e., PK samples) to refine and feedback
estimates of individual PK characteristics to the AFC algorithm, is generally a substantially more
informative dose optimization approach than traditional TDM [94]. In view of the less complex PK and
assay issues for polymyxin B relative to colistimethate/colistin, polymyxin B is likely the superior of
the two agents for the application of AFC.
In their analysis, Lakota and co-workers [59] used a previously developed population PK
model [88] to develop an AFC algorithm for polymyxin B which was evaluated using Monte Carlo
simulations of 5000 simulated patients. Without AFC, a daily polymyxin B dose of 2 mg/kg, computed
based on the population average polymyxin B clearance of 0.0276 L/h/kg to achieve a plasma
polymyxin B Css,avg of 3 mg/L (i.e., the middle of the target window of 2–4 mg/L discussed in
Section 4.1) was applied to all simulated patients. This ‘one dose fits all’ daily dose resulted in
only 71% of simulated patients achieving a plasma polymyxin B Css,avg within the 2–4 mg/L range.
Worryingly, 19.8% of simulated patients had a Css,avg above 4 mg/L and the highest predicted Css,avg
was >8 mg/L. When individualized doses were computed using the AFC algorithm with only one
PK sample collected at 12 h after the first dose in the regimen, 93.6% of simulated patients achieved
exposures within the target Css,avg window of 2–4 mg/L and only 5.0% of patients had exposures
above 4 mg/L. The corresponding probability of target attainment with a single PK sample collected
24 h after the first dose was 95.3% with 2.5% above the upper end of the target window. With 3 or
4 PK samples collected during the first day, the probability of target window attainment increased
to >99% [59]. Clearly, this approach has substantial promise to aid the selection of optimized and
individualized polymyxin B daily doses. Prospective clinical studies to evaluate AFC for polymyxin B
therapy are eagerly awaited.
4.2.4. Dosage Interval and Infusion Duration
Traditionally, dosing guidelines have proposed that the intravenous administration of the
chosen daily dose of a polymyxin should be in 2 or 3 divided doses, i.e., a dosage interval of 12
or 8 h. Based on the established clinical practice of the once-daily administration of aminoglycoside
antibiotics in order to decrease the potential for nephrotoxicity [95,96], there has been interest in the
possibility that the influence of dosage interval may also apply to polymyxin-induced nephrotoxicity.
Wallace et al. [97] were the first to explore this possibility for colistimethate in a rat model. In that study,
the regimen corresponding to once-daily administration in humans resulted in a greater number and
severity of renal lesions than in rats that received the same daily dose in a regimen corresponding to
twice-daily administration in humans. It was proposed that extended-interval dosing resulted in higher
concentrations of colistimethate and colistin in renal tubular cells, which predispose to nephrotoxicity
due to concentration-dependent toxicity [97]. In contrast, Abdelraouf et al. [98], who also employed a
rat model, found lower nephrotoxicity of polymyxin B when administered in a once-daily regimen
relative to the same daily dose administered in divided doses, 6 hourly. It was suggested that this
finding may have been the result of a greater saturation of the carrier-mediated uptake of polymyxin
B from tubular urine into cells with the once-daily regimen [98], but other mechanisms may have
been involved [63]. Importantly, in a multicenter retrospective clinical study, Okoduwa et al. [99]
observed, using propensity score matching of 100 patients in each regimen, that nephrotoxicity was
more common with once-daily than twice-daily dosing of polymyxin B (47% versus 17%, respectively;
p = 0.0005). This finding is consistent with the results of Wallace et al. who used a rat model [97].
Until the results of appropriately powered prospective clinical studies are available, it is prudent to
divide the daily dose to minimize the risk of nephrotoxicity, an approach which may also reduce the
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potential for the development of bacterial resistance based on the results of in vitro studies against
P. aeruginosa [100,101].
Due to the concentration-dependent toxic effect of polymyxin on renal tubular cells [11,98], the
likelihood of nephrotoxicity may possibly increase as the infusion duration is decreased, i.e., a shorter
duration of infusion leads to a higher plasma concentration during and soon after the infusion.
Unfortunately, the possible effect of the duration of infusion of each maintenance dose on the risk of
nephrotoxicity has not been evaluated in appropriately designed and powered clinical studies. It is
recommended that colistimethate be infused over 0.5 to 1 h, and polymyxin B over at least 1 h [51].
5. Other Strategies to Reduce Nephrotoxicity
Obviously, general measures such as strict monitoring of renal function during therapy as
well as maintaining an adequate fluid and electrolyte balance are essential components of the
strategies that may reduce the risk of polymyxin-associated AKI [63,102]. As discussed in Section 3,
there are a few potentially modifiable risk factors for polymyxin-associated AKI, such as avoiding
the co-administration of other known nephrotoxic agents whenever possible, and these should be
addressed [51]. Also discussed in that earlier section is the emerging evidence that combination
therapy with colistin may be associated with a lower potential for nephrotoxicity relative to colistin
monotherapy, although the clinical studies were largely retrospective in nature and/or nephrotoxicity
was not the primary or even secondary outcome measure. The potential benefit of combination therapy
in terms of toxicological outcomes requires further evidence from properly designed studies.
Interventions tested to attenuate polymyxin nephrotoxicity have mainly focused on reducing
oxidative stress mechanisms enhanced by these antibiotics. Many anti-oxidative stress agents have
been tested so far, mostly on animal models. The main results are summarized in Table 1. Overall,
the concomitant use of these agents with polymyxins has led to the reduced production of inflammatory
and oxidative stress biomarkers [103–106]. Attenuation of both cellular apoptosis and histopathological
changes in mice kidneys has been shown as well [103,105,107–109]. Nevertheless, not all studies have
shown significant changes in serum creatinine values when comparing polymyxins prescribed alone
or combined with anti-oxidant drugs [106,110], possibly because after a renal insult, there is a delay in
the response of the serum creatinine concentration.
Clinical studies exploring this issue are still scarce. Ascorbic acid has been the most explored
agent due to its safety profile and encouraging results when used with other nephrotoxic agents. It is
a chain-breaking antioxidant that has previously been shown to reduce contrast medium-associated
nephrotoxicity [111]. One prospective cohort study of septic patients treated with colistin showed that
ascorbic acid was an independently protective factor for AKI [112]. However, a randomized clinical
trial (RCT) that enrolled 28 patients testing the addition of 2 g of ascorbic acid (the same dose that
was demonstrated to be effective in preventing contrast nephrotoxicity) to colistin every 12 h did not
show any benefits in renal function or a reduction of urinary biomarkers for nephrotoxicity in the
intervention group [113]. Although the small number of participants may have limited the power of
the study, the absolute difference in reducing the nephrotoxicity incidence was only 6.2%, favoring the
group that received ascorbic acid. The clinical significance of this small effect could be questionable.
Table 1. Summary of the studies evaluating interventions for the prevention of polymyxin nephrotoxicity.
Study Intervention/Exposure Factor Main Results
Animal Models
Li et al., 2019 [114] Cytochrome C
- Cytochrome C (a megalin ligand) decreased the accumulation of
polymyxin B in the kidney and 24-h N-acetyl-β-D-glucosaminidase
(NAG) in a dose-dependent manner.
- Histological damage was reduced.
- No significant differences in serum creatinine, blood urea nitrogen
(BUN), and blood β2- microglobulin were seen in the groups that
received Cytochrome C compared to the one that received
polymyxin B alone.
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Study Intervention/Exposure Factor Main Results
Animal Models
Ceylan et al., 2018 [108] N-acetylcysteine (NAC)
- Colistin increased the apoptosis index and renal
histological damage score significantly and these changes were
reduced with NAC co-treatment.
- There was no difference between groups regarding total
antioxidant and total oxidant status in the kidneys.
Dai et al., 2017 [105] Baicalein
- Baicalein attenuated colistin-induced oxidative and nitrative stress,
apoptosis, the infiltration of inflammatory cells, and caused
decreases in interleukine-1β and tumor necrosis factor-α levels
(all p < 0.05 or 0.01) in kidney tissues.
- Baicalein attenuated colistin-induced kidney tissue damage on
histopathological analysis, in a dose-dependent manner.
Azad et al., 2017 [103] Methionine
- Histological: polymyxin-induced nephrotoxicity in mice was
ameliorated by methionine in a dose-dependent manner.
- Attenuation of polymyxin-induced mitochondrial superoxide
production in rat kidney cells was observed following pretreatment
with methionine.
- Pharmacokinetics of polymyxin B in rats were not affected
by methionine.
Hassan et al., 2017 [110] Silybin
- Colistin-alone group showed an increase in NAG (p < 0.01) and
reduction of renal function compared to other groups (control,
vehicle and colistin plus silybin) (p < 0.001), but no difference was
found in a direct comparison of colistin plus sybilin group with the
colistin-alone group.
Arslan et al., 2016 [107] Luteolin
- Colistin-treated group had statistically higher number of apoptotic
cells compared to the other three groups (luteolin, luteolin plus
colistin and control) (p = 0.0001) and was the only group to increase
serum creatinine values compared to pre-treatment levels.
- Renal histological damage was also measured and the score of the
colistin-treated group was higher as compared to other groups.
Dai et al., 2015 [104] Lycopene
- Biomarkers of oxidative stress and apoptosis were attenuated in
the kidneys of colistin-treated mice by the co-administration of
lycopene (5 or 20 mg/kg).
Ozkan et al., 2013 [115] Grape seed proanthocyanidinextract (GSPE)
- Colistin + GSPE group showed significant decreases in BUN levels;
creatinine levels; renal histopathological scores; and terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end
labeling, caspase 1 and 3, calpain 1, iNOS, and eNOS staining when
compared to the colistin group alone.
Yousef et al., 2012 [116] Ascorbic acid
- 24-h urinary excretion of NAG was significantly lower in the
groups that received ascorbic acid compared to colistin alone
(p < 0.01).
- The percentage of apoptotic cells decreased in the ascorbic acid
group in a dose-dependent manner (p < 0.0001).
- Ascorbic acid (200 mg/kg) reduced colistin total body clearance.
Yousef et al., 2011 [109] Melatonin
- The addition of melatonin was associated with lower urinary NAG
excretion from day 1 (p < 0.0001).
- Significant histological abnormalities (p < 0.0001) were detected
only in the kidneys of the colistin group. Melatonin altered colistin
pharmacokinetics, reducing total body clearance.
Ozyilmaz et al., 2011 [106] N-acetylcysteine (NAC)
- NAC addition did not change biochemical parameters but reduced
the renal tissue superoxide dismutase level, showing a reduction in
oxidative stress parameters.
Clinical Studies
Dalfino et al., 2015 [112] Ascorbic acid
- 70 patients included. Independent predictors of acute kidney
injury (AKI) were baseline renal impairment (adjusted Hazar Ratio,
4.15; 95% CI 1.9–9.2; p < 0.001) and age (aHR1.03; 95%CI 1.0–1.05;
p = 0.028), whereas ascorbic acid was a protective factor (aHR0.27;
95%CI 12–0.57; p < 0.001).
Sirijatuphat et al., 2015 [113] Ascorbic acid
- Nephrotoxicity incidence was 53.8% (7/13) and 60.0% (9/15) in the
colistin-ascorbic acid group and the colistin group, respectively
(p = 0.956).
- Urinary excretion rates of neutrophil gelatinase-associated
lipocalin and NAG increased during colistin treatment compared to
baselines in both groups (p < 0.05).
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Melatonin is another well-known agent for its anti-oxidative stress properties. Its renal
protective effect has been explored in humans and animal models on a variety of conditions
such as diabetes, hypertension and drug-induced nephropathy [117]. In one study, it showed a
protective effect against colistin-induced AKI in rats [109]. There is currently one RCT registered
in ClinicalTrials.gov (NCT03725267) testing the potential effect of melatonin versus placebo in
polymyxin-induced nephrotoxicity.
Nephrotoxicity is one of the most important drawbacks of polymyxin use and the development of
strategies to overcome this issue is urgently needed. However, most studies are still in the pre-clinical
phase and there is currently insufficient evidence to support the routine implementation of any of
these strategies. This is a vast clinical research field yet to be explored.
6. Conclusions
Despite the recent launch of newer antimicrobial drugs with activity against some
carbapenem-resistant Gram-negative bacteria, polymyxins still have a major role in the therapeutic
arsenal against these organisms and the attenuation of nephrotoxicity of these compounds will continue
to challenge clinicians. The optimization of antibacterial activity without increasing AKI risk is a very
difficult task at the bedside due to the narrow therapeutic window of polymyxins. Ultimately, clinicians
will always be confronted with the dilemma of augmenting drug exposure to improve the odds of
microbiological and, hopefully, clinical success, and, at the same time, increase the probability of
AKI, which is associated with worse outcomes. Minimizing exposure to modifiable risk factors, such
as concomitant nephrotoxic agents, including antibiotics such as vancomycin, along with general
measures such as strict monitoring of renal function and the maintenance of an appropriate fluid
and electrolyte balance during therapy are important to reduce the risk of AKI. The use of oxidative
stress-reducing drugs is a promising therapy but still requires more evidence from clinical studies.
Optimizing therapy with combination regimens to decrease overall AKI rates also deserves further
attention. Finally, dose selection should be rigorously defined in order to avoid the excessive risk of
AKI without compromising antibacterial activity, particularly in high-risk patients such as the elderly,
obese, and those with multiple comorbidities and requiring other nephrotoxic drugs.
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